Journal of Cardiac Failure
Volume 12, Issue 7 , Pages 499-506 , September 2006

Effects of Angiotensin-Converting Enzyme Inhibitors in Systolic Heart Failure Patients With Chronic Kidney Disease: A Propensity Score Analysis

  • Ali Ahmed, MD, MPH

      Affiliations

    • From the Department of Medicine, School of Medicine, and Department of Epidemiology, School of Public Health, and Center for Heart Failure Research, University of Alabama at Birmingham, and VA Medical Center, Birmingham, Alabama
    • Corresponding Author InformationReprint requests: Ali Ahmed, MD, MPH, University of Alabama at Birmingham, 1530 3rd Ave South, CH-19, Ste-219, Birmingham AL 35294-2041.
    • ,
  • Thomas E. Love, PhD

      Affiliations

    • Case Western Reserve University – MetroHealth Medical Center, Department of Medicine, School of Medicine and Department of Operations, Weatherhead School of Management, Case Western Reserve University, Cleveland, Ohio
    • ,
  • Xuemei Sui, MPH

      Affiliations

    • Center for Data Management, the Cooper Institute, Dallas, Texas
    • ,
  • Michael W. Rich, MD

      Affiliations

    • Department of Medicine, School of Medicine, Washington University, St Louis, Missouri

Received 15 April 2005 ,Revised 16 May 2006 ,Accepted 30 May 2006.

References 

  1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation. Endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154–e235
  2. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450–1456
  3. Ruggenenti P, Perna A, Remuzzi G. ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy. J Am Soc Nephrol. 2001;12:2832–2837
  4. Locatelli F, Carbarns IR, Maschio G, et al. Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Kidney Int Suppl. 1997;63:S63–S66
  5. Strippoli GF, Craig M, Deeks JJ, Schena FP, Craig JC. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ. 2004;329:828
  6. Bart BA, Gattis WA, Diem SJ, O'Connor CM. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol. 1997;79:1118–1120
  7. Frances CD, Noguchi H, Massie BM, Browner WS, McClellan M. Are we inhibited? Renal insufficiency should not preclude the use of ACE inhibitors for patients with myocardial infarction and depressed left ventricular function. Arch Intern Med. 2000;160:2645–2650
  8. Ahmed A, Kiefe CI, Allman RM, Sims RV, DeLong JF. Survival benefits of angiotensin-converting enzyme inhibitors in older heart failure patients with perceived contraindications. J Am Geriatr Soc. 2002;50:1659–1666
  9. Hillege HL, Nitsch D, Pfeffer MA, et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 2006;113:671–678
  10. Ahmed A, Centor R, Weaver MT, DeLong JF. A propensity score analysis of the impact of ACE inhibitors on 4-year survival of older adults with heart failure and perceived contraindications. Am Heart J. 2005;149:737–743
  11. Shlipak MG. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med. 2003;138:917–924
  12. The Digitalis Investigation Group . Rationale, design, implementation, and baseline characteristics of patients in the DIG trial: a large, simple, long-term trial to evaluate the effect of digitalis on mortality in heart failure. Control Clin Trials. 1996;17:77–97
  13. The Digitalis Investigation Group . The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525–533
  14. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461–470
  15. Rule AD, Larson TS, Bergstralh EJ, Slezak JM, Jacobsen SJ, Cosio FG. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141:929–937
  16. Chae CU, Albert CM, Glynn RJ, Guralnik JM, Curhan GC. Mild renal insufficiency and risk of congestive heart failure in men and women > or = 70 years of age. Am J Cardiol. 2003;92:682–686
  17. Shlipak MG, Stehman-Breen C, Fried LF, et al. The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis. 2004;43:861–867
  18. Shlipak MG, Fried LF, Stehman-Breen C, Siscovick D, Newman AB. Chronic renal insufficiency and cardiovascular events in the elderly: findings from the Cardiovascular Health Study. Am J Geriatr Cardiol. 2004;13:81–90
  19. National Kidney Foundation . K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002;39:S1–266
  20. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55
  21. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757–763
  22. Joffe MM, Rosenbaum PR. Invited commentary: propensity scores. Am J Epidemiol. 1999;150:327–333
  23. Rubin DB. Using propensity score to help design observational studies: application to the tobacco litigation. Health Serv Outcomes Res Methodol. 2001;2:169–188
  24. Braitman LE, Rosenbaum PR. Rare outcomes, common treatments: analytic strategies using propensity scores. Ann Intern Med. 2002;137:693–695
  25. Normand ST, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54:387–398
  26. Brener SJ, Lytle BW, Casserly IP, Schneider JP, Topol EJ, Lauer MS. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation. 2004;109:2290–2295
  27. Ahmed A, Rich MW, Love TE, et al. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006;27:178–186
  28. Love TE. Doing propensity analysis: the basics and matching. Available online at http://www.chrp.org/propensity/. Accessed: June 4, 2005.
  29. Rosenbaum PR. Observational studies. New York: Springer-Verlag; 2002;
  30. Levesque R. Macro. In: Levesque R, ed. SPSS® programming and data management, ed 2. A guide for SPSS® and SAS® users. Available online at: http://www.spss.com/spss/data_management_book.htm. Accessed: June 4, 2005.
  31. SPSS for Windows,Rel 13. [computer program] Chicago: SPSS Inc; 2005;
  32. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol. 2004;15:2195–2203
  33. Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners?. Int J Cardiol. 1997;59:7–10
  34. The SOLVD Investigators . Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302
  35. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176–186
  36. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J. 2005;26:1115–1140
  37. Ahmed A. Use of angiotensin-converting enzyme inhibitors in patients with heart failure and renal insufficiency: how concerned should we be by the rise in serum creatinine?. J Am Geriatr Soc. 2002;50:1297–1300
  38. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?. Arch Intern Med. 2000;160:685–693

 Preliminary results based on this analysis were presented at the Scientific Sessions of the 2004 American Heart Association national meeting in New Orleans, LA.Dr. Ahmed is supported by Grants 1-K23-AG19211-04 from the National Institutes of Health/National Institute on Aging and 1-R01-HL085561-01 from the National Institutes of Health/National Heart Lung and Blood Institute.

PII: S1071-9164(06)00277-6

doi: 10.1016/j.cardfail.2006.05.008

Journal of Cardiac Failure
Volume 12, Issue 7 , Pages 499-506 , September 2006

Article Tools

* Image Usage & Resolution